Anglo-Swedish pharmaceutical giant AstraZeneca has announced an investment of over $1 billion in Massachusetts as part of its broader $50 billion US expansion plan, expanding its local workforce by >50% in the coming years.
📌 Key Details & Critical Numbers:
- R&D Hub Opening: Unveiled a new 570,000-square-foot, 18-story research and development facility in Kendall Square, Cambridge, Massachusetts.
- Next-Gen Tech: The facility features 10 floors of advanced laboratories equipped with robotics, automation, and artificial intelligence.
- Scientific Workforce: Combined with its nearby genomic medicine site, the hub will house nearly 2,000 researchers and scientists focusing on oncology, chronic and rare diseases, and cell therapies.
- US Footprint: Complements AstraZeneca’s existing major US research center in Gaithersburg, Maryland. The company currently employs >25,000 people across 24 US sites.
- Industry Context: Joins global peers like Pfizer, Roche, and Eli Lilly in deploying multi-billion-dollar investments to bolster US domestic manufacturing, R&D capacity, and supply chain resilience.
AstraZeneca’s state-of-the-art facility underscores the growing integration of AI and robotics in accelerating life-saving biopharmaceutical development.